Enlivex CMO reports initial share and option stake

Enlivex Ltd. Chief Medical Officer Einat Galamidi filed an initial ownership report showing her equity stake in the company.

Rhea-AI Filing Summary

Enlivex Ltd. Chief Medical Officer Einat Galamidi filed an initial ownership report showing her equity stake in the company. She holds 156,304 Ordinary Shares, par value NIS 0.40 per share, directly. She also holds employee stock options over 25,000 shares at an exercise price of $5.3400 per share expiring on March 29, 2032, and options over 10,000 shares at $3.2100 per share expiring on February 15, 2034. The filing does not show any new purchases or sales, only current holdings.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Galamidi Einat

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Employee Stock Option (right to buy)	--	--	--
holding	Employee Stock Option (right to buy)	--	--	--
holding	Ordinary Shares, par value NIS 0.40 per share	--	--	--

Holdings After Transaction: Employee Stock Option (right to buy) — 35,000 contracts (Direct); Ordinary Shares, par value NIS 0.40 per share — 156,304 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Enlivex (ENLV) Form 3 filing by the CMO show?

The Form 3 shows Enlivex’s Chief Medical Officer Einat Galamidi’s existing equity stake. She directly holds 156,304 Ordinary Shares plus employee stock options over 35,000 shares at fixed exercise prices and future expiration dates, with no new purchases or sales reported.

How many Enlivex (ENLV) ordinary shares does the CMO own?

Einat Galamidi directly holds 156,304 Enlivex Ordinary Shares, par value NIS 0.40 per share. This position is reported as of the Form 3 date and represents her current direct share ownership, separate from any employee stock options listed in the same filing.

What stock options are reported for Enlivex (ENLV) CMO Einat Galamidi?

She holds employee stock options over 25,000 Ordinary Shares at an exercise price of $5.3400 expiring March 29, 2032, and 10,000 shares at $3.2100 expiring February 15, 2034. These options provide future rights to buy Enlivex shares at those fixed prices.

Does the Enlivex (ENLV) CMO Form 3 indicate any insider buying or selling?

No, the Form 3 does not indicate insider buying or selling. It is an initial ownership report listing existing holdings: 156,304 Ordinary Shares and two employee stock option positions, without any reported transactions that change those positions on the filing date.

Why is Enlivex (ENLV) Chief Medical Officer filing a Form 3?

A Form 3 is required when someone becomes a company insider such as an officer. This filing records Einat Galamidi’s initial ownership in Enlivex, detailing her direct Ordinary Share holdings and employee stock options at specified exercise prices and expiration dates.

How large is the Enlivex (ENLV) CMO’s option-based exposure?

She holds options tied to 35,000 Enlivex Ordinary Shares in total: 25,000 underlying shares at a $5.3400 exercise price and 10,000 underlying shares at $3.2100. These derivatives supplement her 156,304 directly held shares reported in the same Form 3.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 07:01 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Galamidi Einat

(Last) (First) (Middle)

14 EINSTEIN STREET

(Street)

NESS ZIONA 7403618

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Enlivex Ltd. [ ENLV ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares, par value NIS 0.40 per share	156,304	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	11/24/2025	03/29/2032	Ordinary Shares, par value NIS 0.40 per share	25,000	$5.34	D
Employee Stock Option (right to buy)	11/24/2025	02/15/2034	Ordinary Shares, par value NIS 0.40 per share	10,000	$3.21	D

Explanation of Responses:

Remarks:

See Exhibit 24.1 - Power of Attorney

	/s/ Shachar Shlosberger, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)